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Abstract
Glial cell line-derived neurotrophic factor (GDNF) is a member of the transforming growth factor-b superfamily that when exogenously
administrated exerts a potent trophic action on dopaminergic (DA) cells. Although we know a lot about its signalling mechanisms and
pharmacological effects, physiological actions of GDNF on the adult brain remain unclear. Here, we have used morphological and
molecular techniques, and an experimental model of Parkinson’s disease in rats, to investigate whether GDNF constitutively
expressed in the adult mesostriatal system plays a neuroprotective role on midbrain DA cells. We found that although all midbrain DA
cells express both receptor components of GDNF (GFRa1 and Ret), those in the ventral tegmental area (VTA) and rostromedial
substantia nigra (SNrm) also contain GDNF but not GDNFmRNA. The levels of GDNFmRNA are significantly higher in the ventral
striatum (vSt), the target region of VTA and SNrm cells, than in the dorsal striatum (dSt), the target region of DA cells in the
caudoventral substantia nigra (SNcv). After fluoro-gold injection in striatum, VTA and SNrm DA cells show triple labelling for tyrosine
hydroxylase, GDNF and fluoro-gold, and after colchicine injection in the lateral ventricle, they become GDNF-immunonegative,
suggesting that GDNF in DA somata comes from their striatal target. As DA cells in VTA and SNrm are more resistant than those in
SNcv to intracerebroventricular injection of 6-OHDA, as occurs in Parkinson’s disease, we can suggest that the fact that they project
to vSt, where GDNF expression is significantly higher than in the dSt, is a neuroprotective factor involved in the differential
vulnerability of midbrain DA neurons.
Introduction
Glial cell line-derived neurotrophic factor (GDNF) is a distant member
of the transforming growth factor-b superfamily that together with
neurturin, artemin and persephin form the GDNF family of ligands
(Airaksinen et al., 1999; Baloh et al., 2000). They exert trophic
actions on different cell populations (Henderson et al., 1994; Arenas
et al., 1995; Tomac et al., 1995a; Viglietto et al., 2000; Dressler, 2002)
by means of a receptor complex composed of a specific high-affinity
ligand binding protein, the glycosylphosphatidylinositol-anchored
GDNF receptor a component (GFRa1 GFRa4, GFRa1 for GDNF),
and a common tyrosine kinase subunit (Ret) that acts as the signalling
component (Jing et al., 1996; Saarma, 2000, 2001; Paratcha et al.,
2001; Sariola & Saarma, 2003). Since its characterization and the
identification of its neurotrophic effects on mesostriatal dopaminergic
(DA) cells (Lin et al., 1993), a great deal of interest has been focused
on the potential relevance of GDNF in the treatment of Parkinson’s
disease (PD). On the basis of studies showing that when exogenously
administrated, GDNF supports survival and rescues damaged DA cells
in culture (Bourque & Trudeau, 2000; Ma et al., 2000) and in animal
models of PD (Gash et al., 1995; Bilang-Bleuel et al., 1997; Grondin
& Gash, 1998; Bjorklund et al., 2000; Kordower et al., 2000; Grondin
et al., 2002; Maswood et al., 2002; Grondin et al., 2003) to a higher
degree than other neurotrophins (Krieglstein, 2004), GDNF has been
proposed as a solid candidate for neuroprotective therapy in PD, and
numerous studies have been focused on its successful application to
parkinsonian patients (Kordower et al., 1999; Gill et al., 2003; Nutt
et al., 2003). In spite of the advances in our knowledge about its
signalling mechanisms and pharmacological effects, basic aspects
about the physiological role of GDNF remain unclear. For example,
we do not know whether constitutively expressed GDNF exerts a
neuroprotective role in the adult mesostriatal system. In addition,
although different studies indicate that in adulthood, midbrain DA
cells express both receptor components of GDNF (Trupp et al., 1996;
Golden et al., 1998; Walker et al., 1998; Sarabi et al., 2001), data
about GDNF expression vary from author to author, and some of them
report that its striatal levels decrease during postnatal development
(Stromberg et al., 1993; Springer et al., 1994; Blum &Weickert, 1995;
Choi-Lundberg & Bohn, 1995), suggesting that in adulthood its
neuroprotective effect may be irrelevant. The fact that GDNF does or
does not exert a neuroprotective role on adult mesostriatal cells may be
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a key factor in the pathophysiology of PD. Furthermore, its expression
pattern may influence the differential vulnerability displayed by
different DA cell populations in PD (Fearnley & Lees, 1991; Gibb &
Lees, 1991; Damier et al., 1999) and against different neurotoxins
(Chiueh et al., 1985; Schneider et al., 1987; Herrero et al., 1993;
Varastet et al., 1994; Rodriguez et al., 2001b). Bearing in mind these
arguments, the aim of the present study was to investigate the
expression pattern of GDNF and its receptor components in the adult
mesostriatal system and the possible relation between them and
neuroprotection in mesostriatal DA cells. We have used immunohist-
ochemistry, in situ hybridization, reverse transcriptase-polymerase
chain reaction, injection of retrograde tracers, and an experimental
model of PD in rats that reproduces the topographical pattern of cell
degeneration observed in PD (Rodriguez et al., 2001a,b).
Materials and methods
Male Sprague–Dawley rats (Panlab, Barcelona) weighing 300–350 g
were housed at 22 C, two per cage, under normal laboratory
conditions in a standard 12-h light : 12-h dark schedule (lights on
between 08:00 h and 20:00 h) with free access to food and water.
Experimental protocols were in accordance with the European
Communities Council Directive of 24 November 1986
(86 ⁄ 609 ⁄ EEC) regarding the care and use of animals for experimental
procedures. All efforts were made to reduce the number of animals
used.
Tissue preparation for morphological study
The animals were deeply anaesthetized (chloral hydrate, 400 mg ⁄ kg,
i.p.) and transcardially perfused with 0.9% saline (150 mL) and a
fixative solution (400 mL) of 4% paraformaldehyde in 0.1 m phos-
phate-buffered saline pH 7.4 (PBS). The brains were removed and
stored in the same fixative at 4 C for 6 h. Midbrains and forebrains
were initially obtained using a brain blocker (Activational System,
Warren, MI), immersed overnight at 4 C in a cryoprotective solution
of 30% sucrose in the same buffer, and then cut into 30-lm coronal
sections with a freezing microtome. Sections were collected in
6–8 parallel series and processed by in situ hybridization histo-
chemistry (ISH), immunohistochemistry, double-immunofluorescent
labelling or a combination of immunofluorescence and retrograde
fluoro-gold transport. Solutions used in the fixation and cryoprotection
of material processed by in situ hybridization were treated with 0.1%
diethylpyrocarbonate (DEPC) and autoclaved to inactivate RNases.
Immunohistochemistry and double immunofluorescent labelling
Midbrain sections were processed by single TH, Ret, GFRa1 and
GDNF immunocytochemistry and TH-GDNF double immunofluores-
cence. For single immunolabelling, sections were immersed for
20 min in 3% H2O2 to inactivate endogenous peroxidase, and
incubated for 60 min at room temperature (RT) in 4% normal goat
serum (NGS, Jackson ImmunoResearch, West Grove, PA), or normal
donkey serum (NDS, Jackson ImmunoResearch) in the case of
GFRa1, in PBS containing 0.05% Triton X-100 (Sigma), and
overnight in PBS containing 2% NGS (or 2% NDS) and one of the
primary antibodies, mouse anti-TH monoclonal antibody (1 : 14 000;
Sigma, St. Louis, MO), rabbit anti-Ret polyclonal antibody (1 : 400;
Santa Cruz Biotechnology, Santa Cruz, CA), goat anti-GFRa1
polyclonal antibody (1 : 400, Santa Cruz Biotechnology), or rabbit
anti-GDNF polyclonal antibody (1 : 400; Santa Cruz Biotechnology).
After several rinses, the sections were incubated for 2 h in either
biotinylated goat anti-mouse antiserum (1 : 1200, Jackson Immuno-
Research), biotinylated goat anti-rabbit antiserum (1 : 1200, Jackson
ImmunoResearch) or biotinylated donkey anti-goat antiserum
(1 : 1200, Jackson ImmunoResearch), and 1 : 200 NGS (or 1 : 200
NDS) in PBS. Immunoreactions were visible after incubation for 1 h
at RT in ExtrAvidin-peroxidase (1 : 5000, Sigma) in PBS, and after
10 min in 0.005% 3¢-3¢-diamiobenzidine tetrahydrochloride (DAB,
Sigma) and 0.001% H2O2 in cacodylate buffer 0.05 m pH 7.6. After
several rinses in PBS, the slides were dehydrated, cleared in xylene,
and coverslipped with DPX (BDH Chemicals, Poole, England).
Double-immunofluorescent labelling was studied by using epiflu-
orescence and confocal microscopy. In both cases, the sections were
first incubated for 1 h in 4% NGS and 0.05% Triton X-100 in PBS,
and then overnight in the same solution containing mouse anti-TH
monoclonal antibody (1 : 8000) and rabbit anti-GDNF polyclonal
antibody (1 : 200). Epifluorescent labelling was visible after incuba-
tion for 3 h in Fluorescein Isothiocyanate-conjugated goat anti-mouse
IgG (1 : 150; Jackson ImmunoResearch) and Lissamine Rhodamine-
conjugated goat anti-rabbit IgG (1 : 150; Jackson ImmunoResearch)
in PBS containing 1 : 200 NGS. Confocal images were visible after
incubation for 2 h in Alexa Fluor 546-conjugated goat anti-mouse
IgG (1 : 100; Molecula Probes, Eugene, OR) and Alexa Fluor 488-
conjugated donkey anti-rabbit IgG (1 : 100; Molecula Probes) in PBS
containing 1 : 200 NGS and 1 : 200 NDS. After several rinses,
sections for epifluorescence were air dried, coverslipped with
Vectashield (Vector, Burlingame, CA), and examined under a
fluoromicroscope (Leica Microsystems; Wetzlar, Germany) using
appropriate filters. Sections for confocal microscopy were air dried,
immersed in toluene, coverslipped with Entellan (Merk; Darmstadt,
Germany) and examined under a laser scanning confocal microscope
(LSM 510 META, Zeiss; Overkochen, Germany) equipped with an
argon laser with excitation wavelengths of 458, 477, 488 and 514 nm
and with one helium-neon laser with an excitation wavelength of
543 nm. To ensure the appropriate visualization of labelled elements
and to prevent false positive results, the emission from the argon laser
at 488 nm was filtered through a band pass filter of 505–530 nm, this
emission was colour–coded in green. The emission from the excitation
with the helium laser at 543 nm was filtered through a band pass filter
of 560–615 nm, and colour-coded in red. For each immunocytochem-
istry and immunofluorescence, control experiments were performed by
removing the primary antibody, resulting in negative staining.
In situ hybridization histochemistry
The antisense and the control sense rat digoxigenin-labelled GDNF
riboprobes used in this study were produced by in vitro transcription
of GDNF cDNA obtained by PCR. Total rat RNA was isolated from
rat striatum by using Trizol reagent (Life Technologies, Gaithersburg,
MD). The cDNA was obtained by incubating 2 lg of total RNA,
1 mm dNTP mix, 3 mm DTT, 5 pm hexamers, 40 U RNase inhibitor
(Promega, Madison, WI) and 200 U M-MLV reverse transcriptase
(Gibco, Carlsbad, CA) in a final volume of 30 lL during 1 h at 37 C.
The full-length GDNF cDNA (644 bp) was amplified by PCR under
the following conditions: 3 lL of total cDNA, 0.3 mm dNTP, 1 mm
MgSO4, 0.2 lm primers and 2.5 U of Platinum ⁄ Pfx ⁄DNA polym-
erase (Invitrogen, Carlsbad, CA) in a final volume of 50 lL. The
primer sequences were: sense 5¢-CTAAGATGAAGTTATGGGATG-3¢
and antisense 5¢-AGGGTCAGATACATCCACACC-3¢. The PCR
product was analysed by electrophoresis, the single band excised,
purified and cloned. The GDNF was transcribed with the appropriate
RNA polymerases to synthesize either the sense or antisense probes
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using commercial reagents (Roche Diagnostics, Mannheim,
Germany). The 50 lL transcription mixture included 1 lg template
cDNA, 1 mm of each ATP, CTP and GTP, 0.7 mm UTP and 0.3 mm
DIG-UTP, 10 mm DTT, 50 U RNase Inhibitor, and 1 U of either T3 or
T7 RNA polymerase. After 2 h at 37 C, the template cDNA was
digested with 2 U of RNase-free DNAse for 30 min at 37 C. Then,
the riboprobes were precipitated by the addition of 100 lL of 4 m
ammonium acetate and 500 lL ethanol and centrifuged at 4 C for
30 min. The quality of the synthesis was monitored by Northern blot.
Midbrain and forebrain floating sections were incubated twice with
0.1% active DEPC ⁄ PBS containing 2% (w ⁄ v) proteinase K for
15 min. After pre-equilibration with 5· SSC (0.75 m NaCl, 0.075 m
NaCitrate), the sections were prehybridized at 58 C for 1 h in
hybridization solution (50% formamide, 5· SSC, 40 lg ⁄mL dena-
tured salmon DNA). The probes were denatured for 5 min at 80 C,
added to the hybridization mix at 400 ng ⁄mL, and the sections were
hybridized in this solution at 58 C for 16 h. Posthybridization washes
included 2· SSC at RT for 30 min, 2· SSC at 65 C for 1 h and
0.1· SSC at 65 C for 1 h. Then, the slides were equilibrated for
5 min in TN buffer (100 mm TrisHCl, 150 mm NaCl, pH 7.5), and
incubated for 2 h at RT with alkaline-phosphatase conjugated anti-
DIG monoclonal antibody (1 : 5000 final dilution in TN with 0.5%
blocking reagent, Roche Diagnostics). After two 15 min washes in TN
buffer, the slides were equilibrated for 5 min in TNM buffer (100 mm
TrisHCl, 100 mm NaCl, 50 mm MgCl2, pH 9.5) and incubated in
substrate solution (NBT and BCIP in TNM buffer, Roche Diagnostics)
for 8 h. Staining was stopped in TE (10 mm TrisHCl, 1 mm EDTA,
pH 8.0), and the slides were dehydrated and mounted. Control
experiments were performed for each ISH by skipping the antisense
riboprobe or using their control sense probe, which resulted in an
absence of staining.
Fluoro-gold injection
A total of seven rats received a single injection of Fluoro-gold (FG,
Florochrome, Denver, CO; 0.1–0.3 lL, 4% w ⁄ v in 0.9% saline) in the
left striatum using a glass micropipette attached to a Hamilton
microsyringe. In three rats the injection was localized in the dorsal
striatum and in the other four in the ventral striatum. After a survival
time of 4–5 days, they were deeply anaesthetized (chloral hydrate,
400 mg ⁄ kg, i.p.) and transcardially perfused. The brains were
removed and processed by TH-GDNF double-immunofluorescence
as described above.
6-Hydroxydopamine (6-OHDA) lesion
Rats were anaesthetized with ketamine (25–40 mg ⁄ kg i.p.; Rhoˆne
Me´rieux; Lyon, France) and xylazine (3–6 mg ⁄ kg i.p.; Bayer,
Leverkusen, Germany), and injected in the third ventricle [midline,
2 mm posterior to bregma and 8 mm below the dura, according to
Paxinos & Watson (1998)] with vehicle (0.9% saline solution with
0.3 lg ⁄ lL ascorbic acid, sham group, n ¼ 5) or a single dose of (300 or
500 lg) of 6-OHDA (6-hydroxydopamine hydrochloride, Sigma, in
7.5 lL of vehicle per injection; 1 lL ⁄minute, 6-OHDA groups, n ¼ 6
in each of them). In order to prevent the degeneration of noradrenergic
cells, the rats were treated with nortriptyline 20 min before injection
(30 mg ⁄ kg in saline, i.p.; nortriptyline hydrochloride, Sigma). Special
care was taken in anaesthesia because in our experience, nortriptyline
significantly increases the effect of ketamine, affecting cardiopulmonary
functions during surgery. Bearing inmind that the bilateral degeneration
of DA cells can cause adipsia and aphagia (Ungerstedt, 1971; Longo,
1973; Zigmond & Stricker, 1973), the intake of water and food was
monitored during the weeks following the 6-OHDA injection, until
ingestion and weight were similar to that of the control rats. These
animals were killed after a survival period of 4 weeks and processed by
TH immunohistochemistry following the protocol described above.
Division of the midbrain DA formation for the morphological
study
Although the midbrain DA formation is composed of three main
regions: A8, A9 and A10 (Dahlstro¨m & Fuxe, 1964), our study was
mainly focused on A9 and A10. Bearing in mind cytoarchitectural and
neurochemical criteria (McRitchie et al., 1996; Gonzalez-Hernandez
& Rodriguez, 2000) and the topographical pattern of degeneration
observed in PD (Bernheimer et al., 1973; Hirsch et al., 1988; Damier
et al., 1999) and different models of PD (Chiueh et al., 1985;
Schneider et al., 1987; Herrero et al., 1993; Varastet et al., 1994;
Rodriguez et al., 2001b), A9 was divided into two subregions: (i) the
caudo-ventro-lateral region of the SN (SNcv), that includes A9 DA
cells in the ventrolateral region of the SN pars compacta (SNC) and
the SN pars reticulata (SNR), and (ii) the rostro-dorso-medial region of
the SNC (SNrm); and A10 into (i) the ventral tegmental area and
parabrachial pigmented nucleus (VTA ⁄ PBP), containing medium and
large cells in the paramedial ventral midbrain and above SNC,
respectively, and (ii) the rostral and caudal linear nuclei and
interfascicular nucleus (Li ⁄ IF), formed by small cells in and close to
the midbrain midline. The morphological study was performed
separately in these four subdivisions.
Tissue preparation for reverse transcriptase-polymerase chain
reaction (RT-PCR) analysis
The ventral midbrain and striatum were dissected from six freshly
obtained rat brains and RNA was extracted using the acid phenol
method. The midbrain region containing A9 and A10 [between
3.00 mm and 4.00 mm rostral to the interaural axis; Paxinos &
Watson (1998] was obtained by using a brain blocker and placed on a
cold plate. With the aid of a stereomicroscopy and using a scalpel for
ophthalmic surgery, the dorsal midbrain was removed and two regions
were dissected in the ventral part; a caudoventrolateral one containing
the two lateral thirds of the SNC and SNR (SNcv), and a
rostrodorsomedial one containing the medial third of the SNC (SNrm)
and A10. In the striatum, bearing in mind the topographical
distribution of mesostriatal DA projections in the rat (Fallon &
Moore, 1978; Gerfen et al., 1987; Jimenez-Castellanos & Graybiel,
1987; Joel & Weiner, 2000), we distinguished two different regions,
the dorsal striatum, which includes the two dorsal thirds of the dorsal
striatum and which is the main target of SNcv, and the ventral
striatum, that includes the ventral third of the dorsal striatum and the
accumbens nucleus and which is the main target of SNrm and A10.
RT-PCR analysis
Two micrograms of total RNA were reverse transcribed after heat
denaturation (5 min, 65 C) and annealing of oligo-dT primers. AMV-
reverse transcriptase (Roche Diagnostics) was used for cDNA
synthesis, under the conditions recommended by the manufacturer,
in a final volume of 20 lL. As a control for the amount of cDNA
synthesized in different samples, 1 lL of a 1 : 5 dilution of the cDNA
was used as a template for PCR amplification of b-actin, a
constitutively expressed gene. One microlitre of undiluted cDNA
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was also used to amplify GDNF (NM_019139) in tubes of 25 lL final
reaction volume. Amplification reactions included 0.2 mm dNTPs,
0.5 lm each primer, 0.5 U Taq DNA polymerase (Promega) and
1· PCR buffer pH 9.0, with final 1.5 mm MgCl2. Thirty cycles of the
following temperature profiles were performed in a MJR thermocy-
cler: 94 C (1 min) 65 C (1 min) 72 C (1 min) for b-actin
amplification, and 94 C (1 min) 58 C (1 min) 72 C (1 min) for
GDNF amplification. Fifteen microlitres of the PCR product were
separated in 5% acrylamide gels, stained with 0.5 lg ⁄mL ethidium
bromide and digital images were captured under UV light. The
sequences of the primers used, and the expected molecular size of the
amplification products are: rGDNF-F 5¢-GACTCTAAGATGAA
GTTATGG-3¢, rGDNF-R 5¢-TTTGTCGTACATTGTCTCGG-3¢; rAc-
tin-F 5¢-AATGAGCGGTTCCGATGCCC-3¢, 482 bp; rActin-R
5¢-GGACAGTGAGGCCAGGATAGA-3¢, 297 bp.
Quantitative analysis
In order to get a quantitative estimate of the relationship between
GDNF expression and neuroprotection, we used cell count and
densitometric analysis in the midbrain and striatum. The parameters
analysed were: (i) number and localization of TH cells showing
immunoreactivity for GDNF; (ii) number and localization of cells
containing GDNFmRNA; (iii) number and localization of TH cells
4 weeks after 6-OHDA injection, and (iv) densitometric analysis of
GDNFmRNA in RT-PCR product. All studies were performed on five
rats per group. Six sections, 180 lm apart from each other in the
rostrocaudal axis, were randomly selected in each rat for cell counting.
In each section, midbrain DA regions were divided into fields of
300 lm · 250 lm, at a magnification of ·200. Only cell profiles with
a sectioned nucleus were analysed. The total number of TH profiles
was compared to that of Cresyl violet-stained cells in order to prevent
a possible underestimation of the number of TH positive cells due to
down-regulation in TH activity in 6-OHDA treated rats.
In RT-PCR, bands were quantified by using a Bio-Rad scanner with
densitometry software. Briefly, a rectangle of uniform size and shape
was placed over each band and the density per area (mm2) was
calculated. The background was subtracted from each measurement.
Statistical analyses
Mathematical analyses were performed using the one-way anova
followed by the Tukey honest test for multiple posthoc comparisons.
Analysis was performed using the Statistica program (Statsoft; Tulsa,
USA). A level of P < 0.05 was considered as critical for assigning
statistical significance.
Results
GDNF and its receptor components in the midbrain
dopaminergic formation
In the rat midbrain we found Ret immunostaining (Fig. 1A) in DA
cells in A8 (retrorubral field), A9 (substantia nigra, SN) and the
different subnuclei of A10; ventral tegmental area (VTA), pigmented
parabrabraquial nucleus (PBP), rostral and caudal linear nuclei (Li)
and the interfascicular nucleus (IF). GFRa1 immunostaining was
found in the same cell groups as Ret and in neurons throughout the
substantia nigra pars reticulata (Fig. 1B). These data agree with
previous studies reporting that midbrain DA cells express both
components of the GDNF receptor (Trupp et al., 1996; Golden et al.,
1998; Sarabi et al., 2001) and that nigral GABAergic neurons express
GFRa1 (Sarabi et al., 2001). In addition, immunohistochemistry for
GDNF revealed that a subpopulation of cells mainly localized in
A10 (Fig. 1C) and the rostro-dorso-medial region of SNC (SNrm;
Fig. 1D–F) contain GDNF. Double labelling for GDNF and TH, using
both epifluorescence (Fig. 2) and confocal images (Fig. 3), confirmed
that they are dopaminergic neurons. In epifluorescence, quantification
of the number of TH cells that contain GDNF in different subregions
of the midbrain dopaminergic formation revealed a decreasing
gradient of double-labelled cells from dorsomedial to ventrolateral
regions (Table 1; Figs 2 and 4A). In the medial region of A10 (IF and
IL), 73% of TH cells contain GDNF; in the lateral region of A10 (VTA
and PBP) this percentage was 54%; in the rostromedial third of the
SNC (SNrm), 38%, and in the two lateral third of SNC and SNR
(SNcv), the percentage was not higher than 8%. In confocal
microscopy, we found that in SNcv numerous DA neurons display
GDNF immunoreactivity (Fig. 3D–F), although their labelling inten-
sity, compared to those in dorsomedial regions, was very low
(compare Fig. 3B and E). This suggests that many A9 and A10 DA
cells contain GDNF, although in SNcv, GDNF levels are too low to be
detected by epifluorescence.
Synthesis of midbrain GDNF
To elucidate whether midbrain GDNF is synthesized by midbrain cells
or by their target in striatum, we performed in situ hybridization and
RT-PCR analysis for GDNF in both the midbrain and striatum (Fig. 5).
Bearing in mind that DA cells containing GDNF are mostly localized
in A10 and SNrm, and as mentioned in the Materials and methods,
that mesostriatal projections follow a well established topographical
pattern (Fallon & Moore, 1978; Gerfen et al., 1987; Jimenez-
Castellanos & Graybiel, 1987; Joel & Weiner, 2000), for RT-PCR
analysis, both the midbrain dopaminergic formation and striatum were
divided into two regions. In the midbrain we distinguished a
dorsomedial region containing A10 and SNrm, and another one
containing SNcv. In the striatum, we distinguished a dorsal region
(dSt) containing the two dorsal thirds of the dorsal striatum, which is
the main target of SNcv, and a ventral region (vSt) containing the
ventral third of the dorsal striatum and the accumbens nucleus, which
are the main target of A10 and SNrm. ISH (Fig. 5A–E) and RT-PCR
(Fig. 5F) revealed GDNFmRNA in the striatum but not in the
midbrain. In addition, both techniques showed topographical differ-
ences in the levels of GDNF expression in striatum. In ISH,
GDNFmRNA positive cells were preferentially localized in the vSt,
with a density of 9.3 ± 2.0 stained cells per mm2 in each section
(Fig. 5C–E), while in the dSt the density of stained cells was 3.1 ± 1.2
(Fig. 5B and E). Consistent with these findings, the levels of
GDNFmRNA levels in RT-PCR analysis were significantly higher in
vSt than in dSt (P < 0.01; Fig. 5F).
To support the hypothesis that GDNF contained in midbrain DA
cells comes from their striatal targets, we found that after injection of
colchicine (an inhibitor of protein transport) in the lateral ventricle, TH
neurons in A10 and SNrm became immunonegative for GDNF
(Fig. 4B and C). In addition, after fluoro-gold (FG) injection in the
striatum, numerous cells in A10 and SNrm displayed TH-GDNF-FG
triple labelling (Fig. 4D–F).
GDNF expression pattern and neuroprotection
The fact that GDNF was preferentially synthesized in the vSt and
retrogradely transported by midbrain DA neurons projecting to this
region suggested that this phenomenon may constitute a resistance
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factor against degeneration for this midbrain DA cell population. To
explore this hypothesis we studied the topographical distribution and
the number of midbrain DA cells containing GDNF after intracere-
broventricular injection (i.c.v.) of 6-OHDA, an experimental model of
midbrain DA cell degeneration in the rat that reproduces the main
behavioural and anatomical landmarks of PD (Rodriguez et al.,
2001a,b). On the basis of our experience in the use of this
experimental model, we used two different doses (300 lg and
500 lg) of 6–OHDA. The lesion degree was evaluated by counting
the number of surviving DA neurons (TH immunoreactive cells)
4 weeks after injection. The effect of i.c.v. injection of 6-OHDA was
bilateral, symmetrical and dose-dependent, and the lesion degree
varied from one region to another (Fig. 4G and H; Table 1). A low
magnification view showed that the distribution pattern of surviving
neurons matches that of DA cells containing GDNF, lying mostly in
A10 and SNrm (compare Fig. 4A and H). Cell count (Table 1)
Fig. 1. Immunohistochemistry for Ret (A), GFRa1 (B) and GDNF (C–F) in frontal sections of the midbrain. Note that Ret-immunoreactive neurons are
preferentially localized in the VTA and SNC, while GFRa1-immunoreactive neurons localize in the VTA, SNC and also in the SNR. C–F show that many neurons
are also immunoreactive for GDNF in the IF, VTA and SNrm, but not in the SNcv. (E) Boxed area on the left in D; (F) boxed area on the right in D. IF,
interfascicular nucleus; SNC, substantia nigra pars compacta; SNcv, caudo-ventro-lateral region of the substantia nigra; SNR, substantia nigra pars reticulata; SNrm,
rostro-dorso-medial region of the substantia nigra. Scale bar, 1 mm (B, for A and B); 600 lm (D); 200 lm (F, for C, E and F).
GDNF and differential vulnerability 1819
ª 2005 Federation of European Neuroscience Societies, European Journal of Neuroscience, 21, 1815–1827
revealed that after i.c.v. injection of 300 lg of 6–OHDA, the number
of TH positive cells in the SNcv decreases to 22% with respect to the
sham-injected group, in the SNrm to 44%, in VTA ⁄ PBP to 62%, and
in Li ⁄ IF to 68%. In 500 lg 6–OHDA injected rats, the effect was
more intense than in the 300 lg 6–OHDA injected ones. In all
regions, with the exception of Li ⁄ IF where only a slight reduction in
the cell number was observed (64%), the number of surviving neurons
decreased significantly; to 6% in SNcv, 29% in SNrm, and 45% in
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Fig. 2. Double immunofluorescence for TH (A, C, D, F and H) and GDNF (B, E, G and I) in midbrain sections. (A and B), interfascicular nucleus; (D, F and H),
boxed areas on the left, middle and right side, respectively, in C. We can see that many neurons in the interfascilular nucleus show double labelling, and that as we
move towards ventrolateral regions the number of TH cells immunoreactive for GDNF decreases (H and I). Arrows in A, D, F and H indicate TH cells that are not
immunoreactive for GDNF. SNcv, caudo-ventro-lateral region of substantia nigra; SNrm, rostro-dorso-medial region of the substantia nigra; VTA, ventral tegmental
area. Scale bar, 100 lm (B, for A and B); 250 lm (C); in 50 lm (I, D–I).
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VTA ⁄ PBP. In addition, after 6–OHDA injection, in each DA midbrain
region, the proportion of TH cells showing GDNF immunoreactivity
was significantly higher than in the control group (Table 1; Fig. 4I
and J), although no differences were found between rats receiving
300 lg and 500 lg of 6–OHDA.
Discussion
Our findings confirm previous studies reporting a complementary
distribution in the expression pattern of GDNF and its receptor
components, with GDNF expression in the striatum and GFRa1 and
Ret expression in mesostriatal DA cells (Trupp et al., 1996; Golden
et al., 1998; Walker et al., 1998; Sarabi et al., 2001). On the other
hand, our findings also show that: (i) the levels of GDNFmRNA are
significantly higher in the ventral striatum than in the dorsal striatum;
(ii) although all midbrain DA cells express both components of the
GDNF receptor, only those lying in A10 and SNrm retrogradely
transport GDNF constitutively synthesized in striatum and (iii) this
population of midbrain DA cells is more resistant to 6–OHDA than
that localized in SNcv, which projects to the dorsal striatum and does
not transport GDNF.
In PD, not all midbrain DA cells display the same degree of
susceptibility to degeneration. Degeneration starts at caudo-ventro-
lateral regions of SN and advances towards rostro-dorso-medial regions
of SN and A10, where many neurons remain intact until the final stages
of the disease (Fearnley&Lees, 1991;Gibb&Lees, 1991;Damier et al.,
1999). In our experimental model, the topographic pattern of degener-
ation is similar to that of PD; neurons in the caudo-ventro-lateral region
of SN are more vulnerable than those in the rostro-dorso-medial region
of SN and A10, suggesting that i.c.v. injection of 6–OHDA is an
appropriate model for studying the differential vulnerability of midbrain
DA cells in the pathogenesis of PD. Bearing in mind that the injection
site was on the midline, a striking fact is that DA neurons near the
midline (Li ⁄ IF), which are exposed to the highest concentration of
TH
A
TH
GDNF
GDNF
TH-GDNF
TH-GDNF
D
B C
E F
Fig. 3. Confocal images showing GDNF immunoreactivity in TH cells in the ventral tegmental area (VTA; A–C) and the caudoventral region of the substantia
nigra (SNcv; D–F). Note that VTA DA cells show a robust GDNF labelling while in most SNcv DA cells GDNF labelling is minimal or absent. Scale bar, 20 lm.
Table 1. Quantification of TH cells in different subregions of the midbrain dopaminergic formation
n Li ⁄ IF VTA ⁄ PBP SNrm SNcv
TH-cells showing GDNF-immunoreactivity in control rats (%) 5 72.7 ± 2.5 54.4 ± 4.6 38.3 ± 3.9 8.1 ± 2.1
TH-cells surviving after i.c.v. injection of 300 lg 6-OHDA (%) 5 68.1 ± 7.2*** 62.0 ± 4.5*** 43.8 ± 5.1*** 22.2 ± 5.9***
TH-GDNF cells after i.c.v. injection of 300 lg 6-OHDA (%) 5 80.8 ± 3.1** 72.1 ± 3.2*** 73.0 ± 5.8*** 71.3 ± 3.3***
TH-cells surviving after i.c.v. injection of 500 lg 6-OHDA (%) 5 63.7 ± 6.4 44.9 ± 8.3**** 29.1 ± 4.2**** 6.2 ± 1.4****
TH-GDNF cells after i.c.v. injection of 500 lg 6-OHDA (%) 5 77.6 ± 3.9* 68.6 ± 1.5*** 69.7 ± 8.0*** 72.8 ± 4.9***
Compared with sham-injected rats (n ¼ 5); with respect to the total number of TH cells; *P < 0.05 v.s. sham; **P < 0.01 v.s. sham; ***P < 0.001 v.s. sham;
****P < 0.01 v.s. 300 lg 6-OHDA.
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Fig. 4. (A) Schematic drawing illustrating the topographic distribution of TH-GDNF double-labelled cells in A10 (Li+IF and VTA+PBP) and A9 (SNrm and
SNcv) dopaminergic groups. Neurons were plotted from three frontal sections separated 180 lm from each other at the level of the exit of the third nerve. One dot
represents four double-labelled cells. (B and C), Double labelling for TH and GDNF in the SNrm after intracerebroventricular injection of colchicine in the lateral
ventricle. Note that TH cells are not immunoreactive for GDNF. (D–F) Triple labelling for TH, GDNF and FG in SNrm neurons after FG injection in striatum. (G and
H), Immunostaining for TH in sham and 500 lg 6-OHDA intracerebroventricularly injected rat. (I and J) Double labelling for TH and GDNF in A10 (Li+IF) after
intracerebroventricular injection of 500 lg of 6-OHDA. Note that the distribution of surviving DA cells (H) matches that of those showing GDNF
immunoreactivity (A), and that most surviving TH cells show GDNF immunoreactivity (I and J). Arrows in B and C indicate the same vessels, in D–F they indicate
triple labelled cells, and in I, two TH cells immunonegative for GDNF. FG, fluoro-gold; IF, interfascicular nucleus; Li, rostral and caudal linear nuclei; SNcv, caudo-
ventro-lateral region of the substantia nigra; SNrm, rostro-dorso-medial region of the substantia nigra. Scale bar, 50 lm (C, for B and C); 40 lm (F and J, for D–F
and for I and J, respectively); 1.5 mm (H, for G and H).
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Fig. 5. (A–D) In situ hybridization for GDNF in the midbrain (A) and striatum (B–D). In the midbrain, GDNFmRNA–cells were not detected. In the ventral
striatum (C and D) GDNFmRNA-cells were more numerous than in the dorsal striatum (B). (D) Boxed area in C. (E) Schematic drawing showing the
topographic distribution of GDNFmRNA-positive cells in the striatum. Stained cells were plotted from two frontal sections separated 180 lm from each other at the
level of the anterior commissure. One dot represents six labelled cells. Boxed areas approximately correspond to striatal regions in B and C. (F) RT-PCR analysis
(top) and densitometric quantification (bottom) of GDNFmRNA expression in the midbrain (A10 & SNrm and SNcv) and striatum (dSv and vSt). Confirming ISH
data (A–D), GDNFcDNA was not amplified in the midbrain, and the levels of GDNFcDNA were significantly higher in the ventral striatum than in the dorsal
striatum. A10, A10 dopaminergic cell group; AC, anterior commissure; CC, corpus callosum; dSt, dorsal striatum; SNcv, caduo-ventro-lateral region of the
substantia nigra; SNrm; rostro-dorso-medial region of the substantia nigra; vSt, ventral striatum. *P < 0.01 v.s. dSt. Scale bar, 1 mm (A); 1 mm (C, for B and C);
300 lm (D).
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neurotoxin, paradoxically display the highest resistance to degeneration,
while those in SNcv, the most distant ones from the injection place,
display the highest vulnerability. The differential vulnerability between
different DA cell subpopulations has been attributed to differences in
their phenotypic profile. So, neurons expressing the calcium binding
protein calbindin have been considered more resistant (Yamada et al.,
1990; Lavoie & Parent, 1991; Gaspar et al., 1994), while those
containing high levels of dopamine transporter (Shimada et al., 1992;
Cerruti et al., 1993; Hurd et al., 1994; Uhl et al., 1994; Gonzalez-
Hernandez et al., 2004), and more recently, those expressing the
homeobox factor Pitx3 (Hwang et al., 2003; Smidt et al., 2004) have
been considered more vulnerable. However, current data about the
neurochemical profile of DA cells do not support that GDNF is involved
in the differential vulnerability because they do not express GDNF and
show no differences in the expression pattern of the GDNF receptor
components (Trupp et al., 1996; Golden et al., 1998; Sarabi et al., 2001;
present study). Interestingly, although DA cells do not contain
GDNFmRNA, those lying in the SNrm and A10 are immunopositive
for GDNF. As these neurons project to the ventral striatum, the striatal
region containing the highest levels of GDNFmRNA, GDNF in DA
somata probably comes from their target cells in the striatum. This
hypothesis is supported by the fact that immunoreactivity for GDNF in
A10 and SNrm DA cells disappears after i.c.v. injection of colchicine,
and by previous studies reportingGDNF retrograde transport after being
injected (Tomac et al., 1995b; Lapchak et al., 1997; Kordower et al.,
2000) or experimentally induced (Naveilhan et al., 1997). The close
parallel between the distribution pattern of DA cells showing immu-
nopositivity for GDNF and those surviving after i.c.v. injection of
6–OHDAsuggests thatGDNF exerts a neuroprotective role onDAcells,
although in this case, neuroprotection does not depend on the
neurochemical profile of DA cells but on the topography of their
projections and the synthesis of GDNF by their target cells. Therefore,
we can distinguish two different populations of mesostriatal DA cells
(Fig. 6), one localized in the SNcv, which projects to the dorsal striatum,
does not transport GDNF and is vulnerable to i.c.v. injection of
6–OHDA, and the other localized in the SNrm and A10, which projects
to the ventral striatum, transportsGDNF and is resistant to i.c.v. injection
of 6–OHDA. Interestingly, a previous study has also reported
differences in the actions of GDNF on A9 and A10 cells (Kholodilov
et al., 2004). In GDNF overexpressing mice, the number of A9DA cells
surviving after the natural cell death occurring during the first postnatal
days is higher than in their wild-type strain, but this effect is transient
because the number of SN DA cells is similar in both strains in
adulthood. In contrast, with respect to A10 cells, this effect is persistent
as the increase in the number of DA cells continues into adulthood.
These data are consistent with our idea that the neuroprotective effect of
GDNF is stronger on dorsomedial than on ventromedial midbrain DA
cells, although factors involved in this phenomenon could include others
apart from topographical differences in its striatal synthesis. On the other
hand, it should be noted that although the count of double-labelled cells
revealed a close relationship between GDNF immunoreactivity and
resistance to 6–OHDA, we found no differences between rats receiving
300 lg and 500 lg of 6–OHDA (see Table 1), suggesting that other
factors could also be involved in the differential resistance of midbrain
DA cells to 6–OHDA or that high doses of 6–OHDA can inhibit the
retrograde transport of GDNF.
Until recently, a large body of evidence suggested that the neuropro-
tective effect of GDNF came from its ability to induce enhancement of
dopaminergic hallmarks in intact and lesioned DA cells. Studies using
acute or chronic administration of GDNF have reported an increase in
neuronal excitability, spontaneous firing rate, release and turnover of
DA, TH immunostaining, number and size of TH cells in the SN and
number of TH fibres in the striatum (Gash et al., 1995; Bilang-Bleuel
et al., 1997; Grondin & Gash, 1998; Bjorklund et al., 2000; Kordower
et al., 2000; Kirik et al., 2001; Grondin et al., 2002; Maswood et al.,
2002; Palfi et al., 2002; Grondin et al., 2003). However, the expression
of a strong dopaminergic phenotype and maintenance of high metabolic
activity contrasts with our idea of neuroprotection because dopamine
metabolism is an important source of reactive oxygen species, which
play a damaging rather than a protective role. Therefore, in spite of the
fact that these effects were observed after exogenous administration of
GDNF, and they probably play a relevant role during the development of
dSt
vSt
high synthesis &
A10
SNrm
SNcv
retrograde transport
           of GDNF  
   no retrograde 
transport of GDNF  
6-OHDA vulnerable
          DA-cells
low synthesis & 
6-OHDA  resistant
         DA-cells
Fig. 6. Schematic representation of the two mesostriatal dopaminergic systems, one originating in the A10 and SNrm, composed of 6-OHDA resistant DA cells that
project to the vSt, where GDNF synthesis is high, and another coming from the SNcv, composed of 6-OHDA vulnerable DA cells that project to the dSt, where
GDNF synthesis is low. A10, A10 dopaminergic cell group; dSt, dorsal striatum; SNcv, caudo-ventro-lateral region of the substantia nigra; SNrm; rostro-dorso-
medial region of the substantia nigra; vSt, ventral striatum.
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DA cells, it is improbable that under physiological conditions they are
responsible for a long-term neuroprotective effect in adulthood.
Interestingly, other studies report that sustained infusion (Lu & Hagg,
1997) or lentiviral vector delivery (Rosenblad et al., 2003; Georgievska
et al., 2004) of GDNF produce a reduction in the levels of mRNA and
protein TH as well as its enzymatic activity, suggesting that GDNF
induces TH down-regulation by acting directly on its gene expression.
On the other hand, it is known that the signalling pathway of GDNF is
regulated by protein and lipid kinases and phospholipases (Saarma,
2000, 2001; Paratcha et al., 2001; Sariola & Saarma, 2003), bymeans of
which it induces THphosphorylation (Salvatore et al., 2004). So, GDNF
can exert its neuroprotective effect acting at transcriptional and
transductional levels in the synthesis of different molecules that
determine phenotypic differences in DA cells. In this respect, it is
interesting to note that the levels of THmRNA and DAT mRNA and
protein (Blanchard et al., 1994; Hurd et al., 1994; Haber et al., 1995;
Gonzalez-Hernandez et al., 2004) are lower inDA cells lying inA10 and
SNrm than in those lying in the SNcv, although the possibility that these
phenotypic differences might be due to differences in GDNF expression
in their target cells remains to be explored.
In spite of the fact that the retrograde transport of GDNF was
described for the first time ten years ago (Tomac et al., 1995b) and
thereafter supported by several studies (Lapchak et al., 1997;
Naveilhan et al., 1997; Kordower et al., 2000), with respect to the
molecular mechanisms underlying this phenomenon, we only know
that it may be internalized together with GFRa1, independently of Ret
tyrosine kinase activity (Vieira et al., 2003), and its functional
meaning remains unknown. In contrast to the neurotrophins (nerve
growth factor, brain derived neurotrophic factor and neurotrophin 3
and 4), whose presence in the soma of afferent neurons is substantiated
by the fact that their biological actions require binding to tyrosine
kinase receptors in axon terminals and the subsequent internalization
and retrograde transport of the complex to the cell body (Grimes et al.,
1996; Howe et al., 2001; Ginty & Segal, 2002), in the case of GDNF,
although we know a lot about its complex signalling biology (Saarma,
2000, 2001 Paratcha et al., 2001; Sarabi et al., 2001), no pathways
currently proposed include internalization and transport of the ligand.
Our results show that GDNF is internalized and retrogradely
transported, not only after being injected or when its overexpression
is experimentally induced, but also under physiological conditions.
Further studies should be addressed to elucidating the molecular
mechanisms responsible for its internalization and transport, and more
importantly, whether this is a new signalling pathway involved in
neuroprotection or only a route for its degradation.
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